TVRD

Announcements

Nothing here yet

Daily updates

• Tvardi Therapeutics reported preclinical findings supporting TTI-109 in ulcerative colitis, showing approximately eightfold higher concentrations in colon tissue than plasma and modulation of STAT3-mediated pathways in chronic colitis models.Sep 26, 2026

FDA designations

Nothing here yet

News

• New preclinical findings further support the potential of Tvardi’s STAT3 inhibitors in ulcerative colitisSep 24, 2026
• Tvardi Therapeutics announced a KOL webinar on the clinical potential of TTI-109 in ulcerative colitis and the evolving treatment landscapeAug 12, 2026
• Tvardi Therapeutics announced additional Phase 2 REVERT IPF dataJan 8, 2026
• Tvardi Therapeutics provides update on preliminary data from Phase 2 REVERT trial in idiopathic pulmonary fibrosisOct 13, 2025
• Tvardi Therapeutics announces completion of enrollment in Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosisMay 27, 2025